Michael B Jordan
Affiliation: National Jewish Medical and Research Center
- Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse modelMichael B Jordan
Department of Immunology, and the Howard Hughes Medical Institute, National Jewish Medical and Research Center, Denver, CO 80206, USA
Blood 101:594-601. 2003..Thus, in AIHA, liposomal clodronate therapy may act like a temporary, medicinal splenectomy. As such, it may prove useful in situations where rapid response to therapy is critical or other medical therapies are inadequate...
- Promotion of B cell immune responses via an alum-induced myeloid cell populationMichael B Jordan
Integrated Department of Immunology, National Jewish Medical and Research Center, University of Colorado Health Sciences Center, 1400 Jackson Street, Denver, CO 80206, USA
Science 304:1808-10. 2004..These studies reveal a key role for a previously unknown accessory myeloid cell population in the generation of humoral immune responses...
- An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorderMichael B Jordan
Integrated Department of Immunology, University of Colorado Health Sciences Center, Denver, USA
Blood 104:735-43. 2004..These studies provide insight into the pathophysiology of HLH, and provide new targets for specific therapeutic intervention in this fatal disorder...
- Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosisMichael B Jordan
Department of Pediatrics, University of Colorado Health Sciences Center and The Children s Hospital, Denver, Colorado, USA
Pediatr Blood Cancer 44:251-4. 2005..However, normal Langerhans cells (LC's) in the skin do not bind alemtuzumab. We sought to determine whether the pathologic LC's of Langerhans cell histiocytosis (LCH) express CD52 and thus could be targeted by this antibody...